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Brucellosis is a common zoonosis, endemic in Mediterranean countries, and caused by bacteria of Brucella genus. Brucellosis is
a systemic infection and the clinical presentation varies widely from asymptomatic and mild to severe disease. Cardiovascular
complications are extremely rare. We present a case of arterial thrombosis in a previously healthy young patient with Brucella
endocarditis. Careful attention must be paid to any sign or symptom of thrombosis in patients aﬀected by brucellosis, regardless
of the presence of endocarditis and cardiovascular risk factors.
1. Introduction
Brucellosis is a common zoonosis, endemic inMediterranean
countries, and caused by bacteria of Brucella genus. Infected
animals and their products, particularly unpasteurized milk
and dairy products, are common sources of infection. Nearly
200 cases have been recently reported every year in Italy,
more than half in Sicily [1, 2]. The clinical presentation
varies widely from asymptomatic and mild to severe disease.
Brucellosis is a systemic infection: spleen, liver, and bone
marrow, rich in reticuloendothelial cells, are the most
frequently involved sites. Cardiovascular, gastrointestinal,
osteoarticular, urogenital, haematological, and neurological
complications may arise [3]. Cardiovascular complications
occur in less than 2 percent of cases, but the 80 percent of
deaths from this disease are due to the onset of endocarditis
[4, 5]. The vascular involvement is quite rare and includes
arterial aneurysm formation in diﬀerent vessels, peripheral
arteritis, arterial thrombosis, cutaneous vasculitis, deep
venous thrombosis, and cerebral vein thrombosis [6–11].
We present here a case of subclavian artery thrombosis in
a patient with Brucella endocarditis.
2. Case Presentation
In March 2011, a 35-year-old man was admitted to the
Institute of Infectious Diseases, “Paolo Giaccone” Univer-
sity Polyclinic in Palermo, because of intermittent fever,
arthralgias, and sweating for two months. He also reported
a one-week history of intermittent pain in his left arm.
He was employed at a slaughterhouse and regularly ate
unpasteurized cheese. On admission, physical examination
showed hepatosplenomegaly and on cardiac auscultation a
3/6 systolic murmur was heard all over the precordium.
Laboratory test results revealed an increase in aspartate
aminotransferase (98U/L, upper normal limit 37U/L), ala-
nine aminotransferase (200U/L, upper normal limit 41U/L),
and C-reactive protein (1.6mg/dL, upper normal limit
1mg/dL). Electrocardiogram (ECG) showed normal sinus
rhythm. A transthoracic echocardiogram was performed
and showed mild aortic and mitral insuﬃciency. A rapid
agglutination test (Rosa Bengala Test) and Wright’s serum
agglutination were performed and they were both positive.
Brucella melitensis was isolated from blood culture. The
patient was treated with oral doxycycline (100mg twice
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a day for 6 weeks) and intravenously (IV) rifampin (450mg
twice a day for 3 weeks). Oral rifampin at the same dose
was administered for a further three weeks after hospital
discharge. Fifteen days after the end of treatment, the patient
had a recurrence of fever, asthenia, and hiporexia. The
physical examination did not show remarkable changes.
Echocardiogram showed an aortic valve vegetation (1.4×0.9
in diameter) with eccentric jet of insuﬃciency, mitral valve
with minimal prolapse of the anterior flap, mild mitral, and
tricuspid insuﬃciency. Laboratory test results revealed a total
white blood count of 3830 cells/mm3, haemoglobin 11.8 g/dL
(normal range 13–17 g/dL), platelet 163000 cells/mm3 (nor-
mal range 150–400 × 103/mm3), erythrocyte sedimentation
rate 6mm/h (upper normal limit 15), C-reactive protein
4.68mg/dL, and lactate dehydrogenase 634U/L (normal
range 240–480U/L).
Brucella melitensis was isolated from blood culture. PCR
assay on blood for detection of Brucella was positive. A
treatment with IV rifampin (450mg twice a day) and oral
doxycycline (100mg twice a day) was resumed and IV
amikacin (1 gr once a day) was started. Nine days after
admission, the patient experienced acute left upper limb
pain. Decreased pulses and decreased skin temperature of
the arm were noticed. Echo Doppler showed thrombosis of
the left subclavian artery. The CT scan showed axillary artery
filling defect with side calcification. Heparin (25000U/24 h)
was administered for ten days and the patient underwent
an aortic valve replacement surgery with prosthesis implan-
tation. The treatment with IV rifampin (450mg twice a
day), IV amikacin (1 gr once a day), and oral doxycycline
(100mg twice a day) was stopped after 45 days. Oral rifampin
and doxycycline, at the same dose, were administered for
further 45 days with complete resolution of symptoms. Blood
cultures became negative after ten days of triple therapy.
3. Discussion
Brucella is able to infect endothelial cells and to induce
a powerful inflammatory response, leading to possible
cardiovascular complications [12]. Endocarditis of native
or, more often, prosthetic valves is the most common
presentation of cardiovascular involvement [13, 14]. Vascular
complications, extremely rare, include arterial aneurysm
in any blood vessels (aorta, brachial, tibioperoneal and
cerebral arteries) and venous and arterial thrombosis with or
without underlying endocarditis [6–11]. The inflammatory
response and the immune reaction to Brucella antigens in
the vessel wall are suggested mechanisms for pathogenesis of
vascular involvement. Endothelial activation in response to
Brucella infection, with upregulation of adhesion molecules
and secretion of proinflammatory chemokines, may play an
important role [12].
It is not clear if Brucella endocarditis in our patient has
been an early presentation (on admission cardiac ausculta-
tion revealed a 3/6 systolic murmur all over the precordium)
or a sign of relapse after 15 days. If endocarditis has been a
relapse, doxycycline plus rifampicin administered during the
first hospitalization has not been an eﬀective regimen. There
is evidence that classical therapeutic regimen (doxycycline
for 6 weeks and streptomycin for 3 weeks) is slightly more
eﬃcacious in preventing relapses compared to doxycycline
(for 6 weeks) and rifampicin (for 6 weeks) [15].
On the other hand, subclavian artery thrombosis can
be considered as a complication of endocarditis or as a
primary vascular complication due to the direct localization
of the microorganism in the subclavian artery. The patient
actually complained about left upper limb pain during the
first hospitalization and this symptom was at that time
interpreted as arthralgias, but thrombosis had probably
already started.
4. Conclusions
Our patient was a young and otherwise healthy man without
cardiovascular risk factors, with an insidious presentation
of the illness. We think that it is mandatory to perform
an accurate cardiac physical examination in patients with
brucellosis at admission and during the followup, especially
in patients not responding to therapy or with relapse. Careful
attention must also be paid to any sign or symptom of
thrombosis in patients aﬀected by brucellosis, regardless of
the presence of endocarditis and cardiovascular risk factors.
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